Color Health, Inc.

BURLINGAME, Calif., Sept. 12, 2024 /PRNewswire/ -- Color Health today announced the appointment of Dr. Rebecca Miksad as Chief Medical Officer, and Josh Sturm as Chief Revenue Officer, effective earlier this year. Dr. Miksad will oversee medical and clinical functions at Color, leading the continued development of Color's Virtual Cancer Clinic and its support for earlier intervention and better management of cancer. Sturm focuses on expanding Color's partnerships with employers, unions, health plans, and the public sector to provide accessible healthcare services that change outcomes and costs for those sponsors and their employees and members. As key members of the leadership team, they will use their expertise to help Color expand the innovation and reach of its offerings, including its comprehensive Virtual Cancer Clinic, a partnership with the American Cancer Society. As a medical oncologist and head of the first High Risk Cancer Genetics Clinic at Boston University School of Medicine, Dr. Miksad brings deep experience in clinical leadership, patient-centered care, and AI healthcare technology. She will play a pivotal role in driving Color's mission to reduce cancer care costs through cutting-edge tools for early detection and care management, such as its copilot tool with OpenAI. Prior to Color, she was Senior Medical Director at Flatiron Health where she focused on real-world evidence generation, analysis, and quality standards. Dr. Miksad was previously an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center. Dr. Miksad earned an MD in research from Cornell University, an MMS from Harvard Medical School, an MPH in Clinical Effectiveness from the Harvard School of Public Health, and a BA in economics from Harvard University. "As an oncologist, I see barriers that patients face to cancer care first hand, especially when they are high risk," said Dr. Miksad. "Color's clinical, technological, and organizational momentum is rethinking cancer care holistically to make structural changes that integrate the latest advancements in cancer care with personalized patient attention–giving us the potential to impact population health one person at a time." Color also welcomed Chief Revenue Officer Josh Sturm earlier this year to lead alignment of customer success and retention, marketing, and sales strategies, with the goal to guide customers towards programs that maximize their potential to reach their employees and members with comprehensive cancer care. A leader in the healthcare and pharmaceutical sectors, Sturm's most recent tenure was as a Vice President at Hinge Health, where he focused on new markets and business development. Sturm also served as a Vice President at Surescripts and at Express Scripts, where he provided strategic oversight and managed significant national accounts. He began his career in sales roles with Allergan and Medicine Shoppe International. Sturm has a BS and BBA from Viterbo University and an MBA from Webster University. "Color's legacy of developing scalable, accessible solutions for healthcare's biggest problems will prove formidable in improving employee and member health at scale," said Sturm. "With cancer being one of the largest cost drivers for employers, organizations are at a critical juncture where they can provide services that are good for the health of both their employees and, ultimately, their financials." "Josh and Rebecca have vital on-the-ground experience in patient and customer relationships that are invaluable in telling the story of what working with a company like Color can do for both companies and individual patients," said Othman Laraki, CEO, Color Health. "Their expertise personifies Color's work taking individual connections and scaling them into health benefits that reach thousands of people, and sets us up to continue expanding the reach and quality of our services for our customers." About Color Health Color is a complete platform for healthcare delivery, providing the technology, infrastructure, and logistics required to distribute large-scale health initiatives to diverse populations. Color works with employers, unions, government agencies, schools, and communities to provide equitable, accessible healthcare services. Color supports access for traditional and distributed workforces, as well as underserved communities, by removing barriers to care. Our model enables screening, counseling, and life-saving treatments to be utilized by more people, wherever they are. Connect with Color on Twitter, LinkedIn, Facebook and . Press Contacts Color Health Alyssa Canter [email protected] (917) 710-0091 Elena Riecke 120/80 MKTG for Color [email protected] (917) 485-1994 SOURCE Color Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ATLANTA and BURLINGAME, Calif., Aug. 21, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and Color Health today announced the launch of their new pilot program to provide free at-home colorectal cancer screening kits to individuals in rural areas and other underserved communities, where barriers to healthcare access often hinder timely screening and early detection. The program, which was recognized by the White House Office of Science and Technology Policy, builds on the ACS and Color broader collaboration to change cancer outcomes through better access to cancer screening, education, and clinical and non-clinical management from diagnosis through treatment and survivorship. Colorectal cancer is highly treatable when detected early through regular screening. The 5-year survival rate for colorectal cancer is 91% when diagnosed and treated at an early stage1. Yet, too many Americans continue to be diagnosed with late-stage cancer or face delays in receiving the treatment they need, with the disparities in outcomes based on where people live, race/ethnicity, socioeconomic status and other factors. Colorectal cancer mortality rates are 23% higher in nonmetropolitan areas than in large metropolitan areas.2 The joint initiative seeks to close these access to care disparities by using existing community resources. Select Federally Qualified Health Centers (FQHCs) and community clinics will be invited to receive fecal immunochemical test (FIT) kits, a simple, effective at-home test for detecting traces of blood in the stool that may indicate colorectal cancer or precancerous conditions, to distribute at no cost to eligible individuals. Invited FQHCs and clinics will be predominantly in non-urban and rural areas and will identify eligible patients and distribute these kits free of charge. Eligible individuals can also order a test kit through flyers at libraries and community centers. "After a decade of delivering population health programs, we have gleaned the biggest impact you can have in reducing barriers to access happens when you meet patients where they live, work, and play," said Othman Laraki, CEO of Color Health. "The free cancer screening program is intended to do just that for access to cancer screening and care for rural communities, starting first with colorectal cancer." "This program is a key component of our overall collaboration with Color to ensure that every individual has access to lifesaving cancer care," said Dr. Karen E. Knudsen, CEO of the American Cancer Society. "Together, we aim to break down barriers to care by supporting equally both those individuals with employer-sponsored coverage and those in rural communities who may lack coverage to take proactive steps toward their health." Key features of the free cancer screening program include: Free Access: The program is entirely free for both clinics and patients. Eligible individuals will receive a FIT kit, along with access to Color Health's support services to navigate the screening process. Patient Support: Color Health will assist patients throughout the screening process, from test activation to result delivery. Patients with abnormal results will be guided back to their healthcare provider for further evaluation and care coordination. Test Results are shared securely with healthcare providers through fax or patient portals, ensuring timely follow-up for patients. Clinic Benefits: Participating clinics will have the opportunity to increase access to at-home cancer screening services for their patients without financial burden, supporting their efforts to enhance community health. Initial distribution of FIT kits began in mid-August, with ongoing support and replenishment provided as needed to participating clinics.3 For more information on the ACS-Color free screening program and how to participate, please visit . About the American Cancer Society The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram. About Color Health Color is a complete platform for healthcare delivery, providing the technology, infrastructure, and logistics required to distribute large-scale health initiatives to diverse populations. Color works with employers, unions, government agencies, schools, and communities to provide equitable, accessible healthcare services. Color supports access for traditional and distributed workforces, as well as underserved communities, by removing barriers to care. Our model enables screening, counseling, and life-saving treatments to be utilized by more people, wherever they are. Connect with Color on Twitter, LinkedIn, Facebook and . 1 American Cancer Society, Survival Rates for Colorectal Cancer Report, 2024 2 American Cancer Society, American Cancer Society's Cancer Disparities Report: Non-Metropolitan Areas, People of Lower Socioeconomic Status, Black and American Indian/Alaska Native People Carry Highest Cancer Burden 3 ACS does not provide clinical care. ACS does not endorse any product or service. SOURCE Color Health

以OpenAI为首的大模型企业们，正在全力开拓医疗市场。 不久前，OpenAI的灵魂人物，创始人兼CEO萨姆·阿尔特曼（Sam Altman）创办了一家名为Thrive AI Health（下文简称Thrive）的医疗AI企业，希望通过AI教练改变慢病患者的行为习惯。不出意外的是，它将采用OpenAI的生成式AI技术。 动脉网根据公开资料发现，自2024年以来，OpenAI正在医疗市场火力全开。不光OpenAI，国内大模型企业也在迅速跟进。根据媒体统计，在近年全球120起大模型相关领域融资事件中，大模型+医疗拿下占比第一——高达15%的大模型融资企业与医疗相关。 医疗领域，正在成为“大模型皇冠上的明珠”。 OpenAI， 在医疗领域火力全开 根据报道，Thrive的高管团队可谓星光灿烂，除了萨姆·奥特曼本人，另外一位联合创始人阿里安娜·赫芬顿则同时是《赫芬顿邮报》和行为改变技术公司Thrive Global的创始人。不仅如此，谷歌前高管德卡洛斯·洛夫（DeCarlos Love）也将加入新公司担任CEO。 这家筹备中的企业还将与斯坦福医学研究所、西弗吉尼亚大学洛克菲勒神经科学研究所以及沃尔顿医学院等多家知名学术机构和医疗中心建立深度合作关系。 用含着金钥匙出生的“富二代”来形容它再恰当不过了。 Thrive将开发一个“AI健康教练”平台，希望能够借助生成式AI技术让慢性病患者获得关于睡眠、营养、健身、压力管理和社交等日常生活中关键健康问题的专业指导，进而通过用户行为的改变降低全球范围内的慢性病发病率。 仅以美国为例，2023年有1.29亿人患有至少一种慢性病，如心血管疾病、抑郁症或者糖尿病等。这些慢性病实际上是可以通过日常行为的改变来加以改善的。 根据外媒报道，Thrive的AI健康教练将利用Thrive Global在医疗上的积累，并引入OpenAI在AI领域的最新发展成果（包括长期记忆能力增强和针对特定领域定制开发的行为指导模型等）。这一生成式AI将基于最新的同行评审科学、生物统计、实验室及其他医学数据，并结合用户的个人偏好数据进行训练。 不过，两位创始人表示Thrive将不会涉足医疗辅助诊断，而是专注于提供健康建议。或许也是为了规避敏感的医疗数据隐私以及监管等问题。 同时，Thrive的产品究竟会以什么形式落地也并未确定，或许会以应用的形式推出，也可能通过各种模式提供，甚至可以通过类似Microsoft Teams这样的应用融合到工作场景之中。 这并不是OpenAI第一次涉足医疗。稍加统计不难发现，在进入2024年以来，OpenAI正在医疗领域火力全开。 最大的新闻莫过于在今年4月，知名药企Moderna宣布与OpenAI合作，将ChatGPT Enterprise部署到Moderna整个公司，并定下在六个月内让所有能够访问数字解决方案的人完全熟练使用生成式AI的目标。 事实上，早在2023年初，Moderna就基于OpenAI的API构建了内部AI聊天机器人mChat，并为80%的员工使用并得到好评。在综合衡量后，Moderna最终决定引入ChatGPT Enterprise。在引入该技术仅两个月后，Moderna已有40%的活跃用户创建了个性化聊天机器人，累计数量达到750个，且每个用户平均每周有120次对话之多。 目前，在OpenAI的支持下，Moderna已经在公司内很多日常场景引入了生成式AI。 比如，Moderna已经将生成式AI作为临床研究团队的数据分析助手，用于审查和分析临床数据潜力，并将这些大型数据集集成并可视化，进而帮助增强团队的临床判断和决策。比如，人工智能可以辅助输入详细审查，在后期临床试验进一步开发之前优先考虑安全性并优化疫苗等场景。 其法规团队也对生成式AI推崇备至。在生成式AI帮助下，法规人员可以快速获得清晰可读的合同摘要，此外，生成式AI还可帮助员工快速获取内部政策，无需像以往一样在数百个文档中大海捞针，极大提高了工作效率。 Moderna的PR团队也在利用ChatGPT Enterprise。他们构建了一个生成式AI聊天机器人，可以辅助创建季度财报电话会议的PPT，另外一个聊天机器人则可以帮助将生涩的生物技术术语转换为平易近人的语言，以便与投资者沟通。 四面开花， 生成式AI正在多个医疗场景落地 除了Moderna，越来越多的医疗企业也在与OpenAI合作，并在不少场景中引入生成式AI。其中，AI健康助理已经成为生成式AI在医疗参与的最为擅长的领域之一。除了前面提到的Thrive，Healthify和Whoop都已与OpenAI合作，利用OpenAI生成式AI的能力构建了AI健康助理，对用户数据进行分析并辅助人工为其提供包括饮食、行为习惯等方方面面的指导。 同时，利用生成式AI在自然语言处理上的巨大优势，作为内部知识库或者辅助文书处理也是目前的热门方向之一。 比如，Oscar Health在2024年成为第一家与OpenAI签署商业伙伴协议的医疗企业。借助OpenAI的技术，Oscar Health构建了AI助手，可以有效跟踪报销，并自动回答有关患者报销的问题。不仅可以将处理报销所需时间缩短了50%，也能保证准确性与人工代理相当或更好。 医疗机构Lifespa将使用生成式AI将手术同意书从密集的医疗法律术语转换为所有患者都更容易阅读的文本，从而使更多患者得以理解手术同意书的内容。儿科医疗机构Summer Health则利用生成式AI帮助医生进行就诊记录整理，将医生处理每次就诊记录文书工作的平均时间从10分钟大幅下降到2分钟。 在方兴未艾的“AI+临床”领域，生成式AI的优势也十分明显。 目前，AI+临床在国外已成为投资热点，仅2023年美国已有大概接近200个AI设计的临床试验。生成式AI可以读取海量的疾病表型和基因信息并进行分析，做出临床适应症选择、临床终点优化以及合格受试者确定。另外，生成式AI还可以分析电子病例，从而帮助药企寻找哪些医院有更多更符合入组要求的病人，并发挥临床监测作用。 在以往，临床试验入组的难点一直在于如何将合适的患者匹配和鉴定出来。人工对海量患者病历进行评估并不是一件现实的事情，这造成大多数临床试验都是由靠近试验地点的患者完成，可能会出现选择偏差。 Paradigm利用OpenAI的GPT-4模型对病例进行提取和分析，从而能够将临床试验最匹配的患者匹配出来。实践证明，生成式AI平台可以在每分钟评估数百名患者，比以往人工每天只能评估50名患者的效率大幅提高，且准确性也比人工提高了10%，显示了生成式AI+临床的广阔前景。 同时，在辅助医生为患者提供更个性化的治疗方案方面，OpenAI的生成式AI也展现出了巨大优势。 比如在6月，一直与美国癌症协会合作，帮助健康计划和雇主等控制癌症的Color Health宣布选择OpenAI作为其AI解决方案提供商。这家企业计划通过GPT-4o将医疗数据与临床知识集成创建名为Copilot的生成式AI，为癌症患者创建个性化的全面治疗计划。 Color Health的Copilot已经在临床试用中体现出了优势。据介绍，Copilot可以帮助医疗机构识别出4倍以上缺失实验室、成像或活检和病理学结果的案例；并且，它可以将临床医生分析患者记录并确定差距的时间从以往的数周大幅降低至平均5分钟的水平。 在生成式AI+医疗应用场景的开拓上，国内跟进速度很快。以直接与OpenAI对标的百度为例，2023年9月，百度健康就发布了首个产业级医疗大模型——灵医大模型。经过近一年发展，该模型目前已经形成了MOE+终端组件+智能体的三层技术架构,并在科普内容、互联网医院、智慧医院、智慧诊疗、开放平台的产品上得到了广泛的应用。 在近日举办的百度健康产业生态大会上，百度健康更是围绕患者就医旅程的各个环节、结合医患药各方的需求，连发4款医疗大模型应用与1款开放平台，有力地推进了这一创新技术的落地。 这4款医疗大模型应用分别是：面向普通用户，为用户提供权威、便捷的健康科普信息和医疗咨询服务的垂直大模型应用AI健康助手；在互联网医疗每一个环节中提供质控、辅助决策等支持，进而帮助医生在互联网医院执业中全面提效的在线医疗Copilot；面向医院端，用于解决患者挂错号、挂不准号和医疗资源紧张等矛盾的AI智慧门诊；以及主要围绕病例生成、患者简报、智能问答等医生常用、耗时场景切入的CDSS+LLM。 此外，百度健康还推出了灵医开放平台，并表示将在灵医开放平台之上为合作伙伴提供医疗服务API和1000万Token免费额度，以及提供20个标准化场景免费共建支持，共同探索医院的智慧服务、企业运营提效、诊后患者管理、高质量的科普创作、互联网诊疗的升级，最终推进AI普惠，再塑智慧赋能的医疗服务体系。 总的来说，OpenAI和百度等生成式AI大厂在医疗场景的这些开拓极具代表性，也将为其他大模型企业进入医疗领域提供落地场景上的参考。 国内生成式AI独角兽， 也在All-in医疗 除了大厂，生成式AI领域的独角兽也正在AI+医疗的道路上一路狂奔。就在近日，国内知名大模型独角兽百川智能宣布完成了A轮融资，融资金额高达50亿元，可能会成为2024年国内AI领域最大规模的融资。 考虑到仅仅约一年半前，百川智能才刚刚成立，这一发展速度也是生成式AI受到重视的最好写照。 引人瞩目的是，百川智能也是长期专注医疗领域，将医疗视为梦想的国内头部大模型企业。 其创始人，同样也是搜狗创始人的王小川在清华大学计算机系学习的时候就选择生物方向做交叉学科研究，对生命科学有着浓厚的情怀。从2016年开始，王小川及麾下企业先后投资了鹰瞳科技、小鹿医馆、百科名医、羽医甘蓝、春雨医生等多家医疗科技企业。 2021年搜狗并入腾讯时，王小川更是在公开信中表示，“往后20年，若能为生命健康和医学的发展尽一份力，为大众健康做出一点贡献，生命就更有意义了”。随后，王小川在2023年创立了百川智能，并笃定“医疗是大模型皇冠上的明珠”。 他认为，大模型对于知识的掌握，对经验的掌握，大模型的多模态能力、记忆能力及思考能力，大模型减少幻觉、沟通共情的能力，所有这些在医疗领域都能够用到。模型能力越好，医学水平就越高，这个过程的上限极高。 正因为此，自成立之日起，百川智能就将“健康”写进了公司愿景，进而成为了国内唯一一家专注医疗健康领域的大模型独角兽。 这一通过大模型打造AI医生的路线与公认人工智能三巨头之一的杰弗里·辛顿的观点高度一致。辛顿一直认为医疗是AI可以发挥作用，并带来巨大善行的领域。他认为，AI已经在很多类型的医疗图像解读上可以媲美优秀的专家，并认为AI在整合大量患者数据方面更加出色，AI医生的时代正在到来。 百川智能的相关负责人在与动脉网交流时表示，医疗是数据密度最高的行业，没有之一。医学指南是病历的压缩，疾病诊断则是基于指南的预测。 “医学科研及临床服务的基础原理和大模型其实在一个范式里”，“医生培养方面，内科医生见多识广、外科医生熟能生巧，也和大模型及具身智能训练方式高度一致”，他向动脉网介绍道。 这位负责人进而表示，百川智能的目标是创造“AI医生”。这将引发医疗供给侧革命：“医疗服务行业的痛点是“无限的需求与有限的供给”，互联网医疗对此增益较少但医疗大模型不同，它能通过打造AI医生/助理实现供给千百倍增加，让医疗服务品质更好、可及性更高、成本更低。” 他向我们描绘了百川智能理想中AI医疗的实现路径，将AI医疗与无人驾驶等级类比，给出了L0-L5的分级。 在百川智能看来，目前的大模型技术已经有能力做到L3级别（LLM）的AI医疗应用，即AI在特定条件下可以辅助推荐治疗方案，并由医生确认。百川智能也将会在近期率先以健康顾问和医生助理的形态落地健康咨询、辅助诊疗等医疗场景。 在下一阶段，百川智能将向L4级别（AGI）发起冲击。到了这一阶段，理想中的AI医生将得以实现。L5级别则是终极的生命大模型，它将可以自主基于真实世界研究不断发现新疗法，实现全病程管理。 此外，百川智能在研发医疗大模型的过程中还总结出医疗大模型必须的素质，即“保下限，提上限”。 所谓“保下限”，是指对医疗风险的重视，确保医疗安全。 “首要关键不是提升准确率，而是错的那部分确保不会引发生命健康严重风险，这是0和1的差异。谁能把医疗风险的安全性做得更好，谁才有在牌局上的资格。”“我们希望把百川医疗大模型打造为国内领先乃至全球领先的足够安全可控的模型。” 对于“提上限”，百川智能认为有不少方面是百川智能在研发医疗大模型时将要去突破的。比如类人交互的情感模型、长程记忆能力、强大的多模态能力和很强的推理规划能力等。 “医疗是大模型皇冠上的明珠不是空话，需要一群有梦想的科学家+数十亿或更多的资金投入数年时间才有机会做好。”“如果只是将医疗当做千行百业的一个，简单微调个应用，我觉得这样的打法是很难做好的。” 据介绍，百川智能目前已聘请包括协和、北医等头部三甲医院的高年资主任、主治医师，以及心理学专家对大模型进行多角度的人工评测。未来，百川智能还将与更多优秀医生及医疗机构合作，持续提升模型能力。 写在最后 不难发现，无论国外国内，无论大厂还是独角兽，生成式AI介入医疗的程度正在不断加深，并快速进化。 随着生成式AI的介入，医疗的业务流程正处于从数字化转向数智化的阶段，这也是生成式AI介入传统企业流程必须要走的第一步。随着未来医疗大模型能力越来越强，真正能够在人类指导下完成一些独立的任务时，服务供给显著变多，行业的普惠性将会在此时出现。 动脉网也将持续关注生成式AI对医疗的推动，并为大家带来相关报道。我们相信虽然困难重重，但不断进化的生成式AI必将会为医疗参与各方带来福祉。 * 参考资料： Alyssa、Panken，智东西：《教父Hinton 46分钟对谈：AI可复制人类心智，或加剧全球贫富差距》 Heather Landi，fiercehealthcare.com：OpenAI Startup Fund, Arianna Huffington back new AI health coach venture focused on chronic conditions 李水清，智东西：《大模型热钱汹涌，半年百个亿级融资，最高超500亿元》 *封面图片来源：123rf 如果您认同文章中的观点、信息，或想进一步讨论，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。 动脉网，未来医疗服务平台